The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study.
 
Shuji Takiguchi
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst)
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Noriaki Takiguchi
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst)
 
Seiji Ito
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Mitsugu Kochi
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst)
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genomic Health (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Kinoshita
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Takaki Yoshikawa
Honoraria - AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; EA Pharma; Johnson & Johnson/Janssen; Medtronic; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; TERUMO
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly
 
Hirotaka Hasegawa
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Fujifilm; Kyowa Kirin; Merck Serono; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Yasuhiro Kodera
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Research Funding - abbott Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Maruho (Inst); MSD (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst)